0000000000134506
AUTHOR
M.h. Guignard
Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma
Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…
Impact économique des stratégies de recours à l’éphédrine en seringues préremplies
Resume Objectifs L’ephedrine est un medicament d’urgence disponible en ampoules necessitant la preparation a l’avance de seringues selon deux strategies dans notre etablissement : la strategie 1 (S1 : 1 ampoule par patient) et la strategie 2 (S2 : 1 ampoule par bloc). Des formes preremplies existent. En raison de leur cout eleve et des resultats divergents de la litterature, nous avons evalue l’interet economique du referencement des seringues preremplies (SPR) en fonction des strategies d’utilisation. Type d’etude Notre etude est prospective et observationnelle. Patients et methodes Les consommations en ephedrine ont ete relevees sur deux periodes de 14 jours : P1 avec preparation a l’avan…
Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.
Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…